

Curriculum vitae

Personal information

Surname(s) / First name(s) **Puthenparampil Marco**

Current Position

Dates From July 2020
Occupation or position held Ricercatore a Tempo determinato di tipo A (RTDa)
Name and address of employer Neurology Clinic, Department of Neurosciences, University of Padua, Via Giustiniani 2, 35128 Padova, Italy

Work experience

Dates September 2018 – September 2019
Occupation or position held Visiting PhD Student, University of Zurich
Name and address of employer Neuroimmunology and MS Research, Department of Neurology, University Hospital Zürich/
University of Zürich, Frauenklinikstrasse 26, 8091 Zürich

Dates October 2016- August 2018
Occupation or position held Lecturer of Neuroimmunology (Optional Course “Clinical and Experimental Neuroimmunology”, School of Medicine, University of Padua; “Neuroimmunology and Autoimmune Disorders of the Central Nervous System”, School of specialisation in Neurology, University of Padua).
Name and address of employer Neurology Clinic, Department of Neurosciences, University of Padua, Via Giustiniani 2, 35100 Padova, Italy

Dates October 2016 – September 2019
Occupation or position held PhD Student, Translational Medicine G.B. Morgagni Course
Name and address of employer Neurology Clinic, Department of Neurosciences, University of Padua, Via Giustiniani 2, 35100 Padova, Italy

Dates October 2008 – May 2011
Occupation or position held Internship
Name and address of employer Prof. P. Gallo, Department of Neurology, University of Padua, Via Giustiniani 2, 35100 Padova, Italy

Education and Training

Dates July 2004
Title of qualification awarded High school diploma from the Liceo ‘E. Majorana - E. Corner’ of Mirano (Venice) - Italy. 84/100;
September 2010
Dates

Title of qualification awarded	09/2004 – 09/2010 Degree in Faculty of Medicine and Surgery at the University of Padua, Italy. 106/110; Thesis: “ <i>Clinical, immunological and MRI follow-up of Relapsing-Remitting Multiple Sclerosis patients treated with Natalizumab</i> ”. Supervisor: Ch.mo Prof. P. Gallo.
Dates	July 2016
Title of qualification awarded	June 2011- June 2016 Degree in Neurology, Department of Neuroscience, University of Padua, Italy. 110/110 cum laude; Thesis: “ <i>The intrathecal syntheses of CXCL13, BAFF and IgGOB probably reflect different phases of B-cell activation. A study in multiple sclerosis at clinical onset</i> ”. Supervisor: Ch.mo Prof. P. Gallo
Dates	March 2020
Title of qualification awarded	Doctor of Philosophy, Translational Medicine G.B. Morgagni Course 110/100 cum laude; Thesis: “ <i>The evaluation of CSF-infiltrating T-cell reactivity allows the identification of Multiple Sclerosis subtypes</i> ”. Supervisor: Ch.mo Prof. E. Pegoraro; Co-supervisor: Ch.mo Prof. M. Sospedra Ramos, PhD

Published Manuscripts

1. Rinaldi F, Calabrese M, Seppi D, **Puthenparampil M**, Perini P, Gallo P. “Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report”. *Neurol Sci.* 2011 Jan;31 Suppl 3:317-20. doi: 10.1007/s10072-010-0346-x
2. Rinaldi F, Calabrese M, Grossi P, **Puthenparampil M**, Perini P, Gallo P. “Cortical lesions and cognitive impairment in multiple sclerosis”. *Neurol Sci.* 2010 Nov;31(Suppl 2):S235-7. doi: 10.1007/s10072-010-0368-4. Review;
3. Rinaldi F, Calabrese M, Seppi D, **Puthenparampil M**, Perini P, Gallo P. “Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis”. *Mult Scler.* 2012 Dec;18(12):1760-7. doi:10.1177/1352458512447704;
4. **Puthenparampil M**, Seppi D, Rinaldi F, Federle L, Calabrese M, Perini P, Gallo P; Multiple Sclerosis Epidemiology Veneto Study Group (MuSEV). “Increased incidence of multiple sclerosis in the Veneto region, Italy”. *Mult Scler.* 2013 Apr;19(5):601-4. doi: 10.1177/1352458512461970;
5. Seppi D, **Puthenparampil M**, Federle L, Ruggiero S, Toffanin E, Rinaldi F, Perini P, Gallo P. “Cerebrospinal fluid IL-1 β correlates with cortical pathology load in multiple sclerosis at clinical onset”. *J Neuroimmunol.* 2014 May 15;270(1-2):56-60. doi: 10.1016/j.jneuroim.2014.02.014. Epub 2014 Mar 6;
6. **Puthenparampil M**, Poggiali D, Causin F, Rolma G, Rinaldi F, Perini P, Gallo P. “Cortical relapses in multiple sclerosis”. *Mult Scler.* 2015 Mar 19. pii: 1352458514564483.
7. **Puthenparampil M**, Miente S, Federle L, Zanetta C, Toffanin E, Ruggiero S, Rinaldi F, Gallo P. “BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset”. doi:10.1016/j.jneuroim.2016.05.013. Available online 16 May 2016.
8. **Puthenparampil M**, Federle L, Miente S, Zito A, Toffanin E, Ruggiero S, Ermani M, Pravato S, Poggiali D, Perini P, Rinaldi F, Gallo P. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset. *J Neuroinflammation.* 2017 Jan 17;14(1):11. doi: 10.1186/s12974-016-0785-2
9. Gaiani A, Martinelli I, Bello L, Querin G, **Puthenparampil M**, Ruggiero S, Toffanin E, Cagnin A, Briani C, Pegoraro E, Sorarù G. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral

- Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. *JAMA Neurol.* 2017 Mar 6. doi: 10.1001/jamaneurol.2016.5398
10. **Puthenparampil M**, Terrin A, Federle L, Gizzi M, Perini P, Gallo P. Acute simultaneous development of brain tumour-like lesion and demyelinating polyneuropathy in a patient with chronic relapsing myelitis. *Mult Scler.* 2017 Aug 1;1352458517714610. doi: 10.1177/1352458517714610. [Epub ahead of print] PubMed PMID: 28795610
 11. **Puthenparampil M**, Federle L, Poggiali D, Miante S, Signori A, Pilotto E, Rinaldi F, Perini P, Sormani MP, Midena E, Gallo P. Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. *PLoS One.* 2017 Aug 29;12(8):e0183957. doi: 10.1371/journal.pone.0183957. eCollection 2017. PubMed PMID: 28850630; PubMed Central PMCID: PMC5574611
 12. Capone F, **Puthenparampil M**, Mallio CA, Celia AI, Florio L, Gallo P, Di Lazzaro V. A new T2 lesion in a patient with the clinically isolated syndrome does not necessarily imply a conversion to multiple sclerosis. *Clin Neurol Neurosurg.* 2018 Jan;164:138-141. doi: 10.1016/j.clineuro.2017.12.009. Epub 2017 Dec 7. PubMed PMID: 29223794
 13. Rinaldi F, Federle L, **Puthenparampil M**, Perini P, Grassivaro F, Gallo P. Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy. *Neurol Neuroimmunol Neuroinflamm.* 2017 Dec 13;5(1):e420. doi: 10.1212/NXI.0000000000000420. eCollection 2018 Jan. PubMed PMID: 29259997; PubMed Central PMCID: PMC5730817
 14. **Puthenparampil M**, Rinaldi F, Federle L, Cazzola C, Perini P, Gallo P. Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon. *Ther Adv Neurol Disord.* 2017 Nov 29;11:1756285617741056. doi: 10.1177/1756285617741056. eCollection 2018. PubMed PMID: 29399047; PubMed Central PMCID: PMC5784536
 15. **Puthenparampil M**, Zito A, Pantano G, Federle L, Stropparo E, Miante S, De Silvestro G, Plebani M, Gallo P. Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset. *Mult Scler.* 2018 Jun 1;1352458518779951. doi: 10.1177/1352458518779951
 16. **Puthenparampil M**, Altinier S, Stropparo E, Zywicki S, Poggiali D, Cazzola C, Toffanin E, Ruggero S, Grassivaro F, Zaninotto M, Plebani M, Gallo P. Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination. *Mult Scler Relat Disord.* 2018 Oct;25:241-245. doi: 10.1016/j.msard.2018.08.002. Epub 2018 Aug 10. PMID: 30130707;
 17. Perini P, Rinaldi F, **Puthenparampil M**, Marcon M, Perini F, Gallo P. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient. *Mult Scler Relat Disord.* 2018 Nov;26:68-70. doi: 10.1016/j.msard.2018.09.009. Epub 2018 Sep 11. PMID: 30227312;
 18. Tateo F, Grassivaro F, Ermani M, **Puthenparampil M**, Gallo P. PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy. *Mult Scler.* 2019 Nov;25(13):1719-1727. doi: 10.1177/1352458518803273. Epub 2018 Oct 1. PMID: 30270719;
 19. **Puthenparampil M**, Cazzola C, Zywicki S, Federle L, Stropparo E, Anglani M, Rinaldi F, Perini P,

- Gallo P. NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis. *Ther Adv Neurol Disord*. 2018 Oct 25;11:1756286418805713. doi: 10.1177/1756286418805713. PMID: 30386435; PMCID: PMC6204617;
20. Grassivaro F, **Puthenparampil M**, Pengo M, Saiani M, Venturini M, Stropparo E, Perini P, Rinaldi F, Freddi N, Cadaldini M, Colledan L, Piccinno MG, Pedrazzoli E, Gallo P. Multiple Sclerosis Incidence and Prevalence Trends in the Province of Padua, Northeast Italy, 1965-2018. *Neuroepidemiology*. 2019;52(1-2):41-46. doi: 10.1159/000493857. Epub 2018 Nov 26. PMID: 30476909;
 21. Riccardi A, **Puthenparampil M**, Rinaldi F, Ermani M, Perini P, Gallo P. D-KEFS ST Failure Identifies Multiple Sclerosis Patients With Worse Objective and Self-Perceived Physical and Cognitive Disability. *Front Psychol*. 2019 Jan 24;10:49. doi: 10.3389/fpsyg.2019.00049. PMID: 30733696; PMCID: PMC6353833;
 22. Federle L, **Puthenparampil M**, Stenta G, Paolo G, Francesco P. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review. *Mult Scler Relat Disord*. 2019 May;30:262-264. doi: 10.1016/j.msard.2019.03.002. Epub 2019 Mar 5. PMID: 30851640;
 23. Faigle W, Cruciani C, Wolski W, Roschitzki B, **Puthenparampil M**, Tomas-Ojer P, Sellés-Moreno C, Zeis T, Jelcic I, Schaeren-Wiemers N, Sospedra M, Martin R. Brain Citrullination Patterns and T Cell Reactivity of Cerebrospinal Fluid-Derived CD4+ T Cells in Multiple Sclerosis. *Front Immunol*. 2019 Apr 10;10:540. doi: 10.3389/fimmu.2019.00540. PMID: 31024521; PMCID: PMC6467957;
 24. Altinier S, **Puthenparampil M**, Zaninotto M, Toffanin E, Ruggero S, Gallo P, Plebani M. Free light chains in cerebrospinal fluid of multiple sclerosis patients negative for IgG oligoclonal bands. *Clin Chim Acta*. 2019 Sep;496:117-120. doi: 10.1016/j.cca.2019.06.016. Epub 2019 Jun 21. PMID: 31233736;
 25. **Puthenparampil M**, Stropparo E, Zywicki S, Bovis F, Cazzola C, Federle L, Grassivaro F, Rinaldi F, Perini P, Sormani MP, Gallo P. Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis. *Front Immunol*. 2020 Mar 5;11:174. doi: 10.3389/fimmu.2020.00174. PMID: 32194540; PMCID: PMC7066207;
 26. Pilotto E, Mianta S, Torresin T, **Puthenparampil M**, Frizziero L, Federle L, Gallo P, Midena E. Hyperreflective Foci in the Retina of Active Relapse-Onset Multiple Sclerosis. *Ophthalmology*. 2020 Dec;127(12):1774-1776. doi: 10.1016/j.ophtha.2020.03.024. Epub 2020 Mar 29. PMID: 32359844;
 27. Scartezzini A, Tateo F, Perini P, Benacchio L, Ermani M, Ferro A, Cadaldini M, Piccinno MG, Colledan L, Freddi N, Gallo P, **Puthenparampil M**. Association of Multiple Sclerosis with PM 2.5 levels. Further evidence from the highly polluted area of Padua Province, Italy. *Mult Scler Relat Disord*. 2021 Feb;48:102677. doi: 10.1016/j.msard.2020.102677. Epub 2020 Dec 6. PMID: 33316725;
 28. Miscioscia A, Rinaldi F, Riguzzi P, **Puthenparampil M**, Gallo P. Encephalopathy as unique manifestation of Sjogren's syndrome: expanding the spectrum of steroid-responsive encephalopathy. *Rheumatology (Oxford)*. 2020 Dec 13:keaa813. doi: 10.1093/rheumatology/keaa813. Epub ahead of print. PMID: 33399847;

29. **Puthenparampil M**, Tomas-Ojer P, Hornemann T, Lutterotti A, Jelcic I, Ziegler M, Hülsmeier AJ, Cruciani C, Faigle W, Martin R, Sospedra M. Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS. *Neurol Neuroimmunol Neuroinflamm*. 2021 Mar 1;8(2):e951. doi: 10.1212/NXI.0000000000000951. PMID: 33649179; PMCID: PMC7963437;
30. Ruiz M, **Puthenparampil M**, Campagnolo M, Castellani F, Salvalaggio A, Ruggero S, Toffanin E, Cacciavillani M, Gallo P, Franciotta D, Briani C. Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies. *J Neurol Neurosurg Psychiatry*. 2021 Apr 13:jnnp-2020-325868. doi: 10.1136/jnnp-2020-325868. Epub ahead of print. PMID: 33850000;
31. Riccardi A, Ognibene F, Mondini S, Nucci M, Margoni M, Meglioranzi I, Carta E, Zywicki S, Miente S, Perini P, Rinaldi F, **Puthenparampil M**, Gallo P. Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi Multipla Autovalutazione Cognitiva, SMAC). A Preliminary Exploratory Pilot Study. *Front Neurol*. 2021 Jun 28;12:668933. doi: 10.3389/fneur.2021.668933;
32. Cruciani C, **Puthenparampil M**, Tomas-Ojer P, Jelcic I, Docampo MJ, Planas R, Manogaran P, Opfer R, Wicki C, Reindl M, Jelcic I, Lutterotti A, Martin R, Sospedra M. T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2021 Sep 17;8(6):e1075. doi: 10.1212/NXI.0000000000001075;
33. **Puthenparampil M**, Perini P, Bergamaschi R, Capobianco M, Filippi M, Gallo P. Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors. *J Neurol*. 2021 Sep 27. doi: 10.1007/s00415-021-10782-5.
34. Tomas-Ojer P, **Puthenparampil M**, Cruciani C, Docampo MJ, Martin R, Sospedra M. Characterization of Antigen-Induced CD4+ T-Cell Senescence in Multiple Sclerosis. *Front Neurol*. 2022 Feb 3;13:790884. doi: 10.3389/fneur.2022.790884
35. Gasparotto M, **Puthenparampil M**, Morra F, Doria A, Ramonda R. Posterior reversible encephalopathy syndrome: an atypical neurological manifestation of SARS-CoV-2 infection. *Neurol Sci*. 2022 Jul;43(7):4103-4105. doi: 10.1007/s10072-022-06040-9
36. Pengo M, Miente S, Franciotta S, Ponzano M, Torresin T, Bovis F, Rinaldi F, Perini P, Saiani M, Margoni M, Bertoldo A, Sormani MP, Pilotto E, Midenza E, Gallo P, **Puthenparampil M**. Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2022 May 23;9(4):e1180. doi: 10.1212/NXI.0000000000001180
37. Miscioscia A, **Puthenparampil M**, Miente S, Pengo M, Rinaldi F, Perini P, Gallo P. Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis. *J Neurol*. 2022 Oct;269(10):5436-5442
38. **Puthenparampil M**, Torresin T, Franciotta S, Marin A, De Napoli F, Mauceri VA, Miente S, Pilotto E, Midenza E, Gallo P. Hyper-Reflecting Foci in Multiple Sclerosis Retina Associate With Macrophage/Microglia-Derived Cytokines in Cerebrospinal Fluid. *Front Immunol*. 2022 May 19;13:852183. doi: 10.3389/fimmu.2022.852183
39. Zanotelli G, Bresciani L, Anglani M, Miscioscia A, Rinaldi F, **Puthenparampil M**. Case Report: Para-infectious cranial nerve palsy after bacterial meningitis. *Front Immunol*. 2022 Oct 6;13:1000912. doi: 10.3389/fimmu.2022;
40. Nosadini M, Eyre M, Giacomini T, Valeriani M, Della Corte M, Praticò AD, Annovazzi P, Cordani R,

- Cordelli DM, Crichiutti G, Di Rosa G, Dolcemascolo V, Fetta A, Freri E, Gallo P, Gastaldi M, Granata T, Grazian L, Iorio R, Lombardini M, Margoni M, Mariotto S, Matricardi S, Melani F, Nardocci N, Papetti L, Passarini A, Pisani F, Po' C, **Puthenparampil M**, Ragona F, Savasta S, Siliquini S, Toldo I, Tozzo A, Turco EC, Varone A, Vogrig A, Zuliani L, Bugin S, Rossato S, Orsini A, Cantalupo G, Mancardi MM, Ferilli MAN, Foadelli T, Sartori S. Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. *Neurol Neuroimmunol Neuroinflamm.* 2022 Nov 29;10(1):e200065. doi: 10.1212/NXI.000000000200065;
41. Signoriello E, Lus G, Saccà F, **Puthenparampil M**, Coppola C, Di Pietro A, Puoti G, Criscuolo MC, Foschi M, Miele G, Abbadessa G, Brescia Morra V, Gallo P, Bonavita S, Sormani MP, Signori A. Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence. *J Clin Med.* 2023 Feb 22;12(5):1768. doi: 10.3390/jcm12051768. PMID: 36902555
42. **Puthenparampil M**, Gaggiola M, Miscioscia A, Mauceri VA, De Napoli F, Zanotelli G, Anglani M, Nosadini M, Sartori S, Perini P, Rinaldi F, Gallo P. Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis. *Ther Adv Neurol Disord.* 2023 Oct 6;16:17562864231177196. doi: 10.1177/17562864231177196
43. Garri F, **Puthenparampil M**, Simonato D, Rinaldi F, Gallo P. A rare case of Listeria rhombencephalitis with a sudden onset and unusual brain MRI features. *Neurol Sci.* 2023 Sep 22. doi: 10.1007/s10072-023-07080-5
44. Sottini A, Quaresima V, Barbaro M, Moiola L, Filippi M, Malentacchi M, Capobianco M, **Puthenparampil M**, Gallo P, Cocco E, Frau J, Zaffaroni M, Guaschino C, Stampatori C, Mancinelli C, Brambilla L, Clerici VT, Vianello M, Vitetta F, Ferraro D, Rosettani P, Danni MC, Conti M, Grimoldi M, Capra R, Imberti L. Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab. *J Neuroimmunol.* 2023 Sep 15;382:578170. doi: 10.1016/j.jneuroim
45. Miant S, Margoni M, Moretto M, Pengo M, Carmisciano L, Spoletini P, Silvestri E, Danieletto M, Franciotta S, Miscioscia A, Bertoldo A, **Puthenparampil M**, Gallo P. Trans-synaptic degeneration in the optic pathway: Exploring the role of lateral geniculate nucleus in early stages of relapsing-remitting multiple sclerosis. *Mult Scler Relat Disord.* 2023 Sep;77:104877. doi: 10.1016/j.msard.2023.104877
46. Miscioscia A, **Puthenparampil M**, Blasi L, Rinaldi F, Perini P, Sorarù G, Gallo P. Neurodegeneration in the retina of motoneuron diseases: a longitudinal study in amyotrophic lateral sclerosis and Kennedy's disease. *J Neurol.* 2023 Sep;270(9):4478-4486. doi: 10.1007/s00415-023-11802-2
47. Marinetto S, Riccardi A, Barbadoro F, Pucci V, Selini E, Pavan A, Rinaldi F, Perini P, **Puthenparampil M**, Gallo P, Mondini S. Sexual Dysfunction in Multiple Sclerosis: The Role of Executive Function. *Behav Sci (Basel).* 2023 Apr 29;13(5):369. doi: 10.3390/bs13050369
48. Maffezzini S, Pucci V, Riccardi A, Montemurro S, **Puthenparampil M**, Perini P, Rinaldi F, Gallo P, Arcara G, Mondini S. Clinical Profiles in Multiple Sclerosis: Cognitive Reserve and Motor Impairment along Disease Duration. *Behav Sci (Basel).* 2023 Aug 25;13(9):708. doi: 10.3390/bs13090708

49. Aprea MG, Schiavetti I, Portaccio E, Ballerini C, Battaglia MA, Bergamaschi R, Bricchetto G, Bunul SD, Calabrese M, Capobianco M, Cavalla P, Celani MG, Clerico M, Cocco E, Comi G, Confalonieri P, Conte A, Cordioli C, De Luca G, De Rossi N, Filippi M, Gumes H, Immovilli P, Inglese M, Karabudak R, Landi D, Lanzillo R, L'Episcopo MR, Lorefice L, Mantero V, Marangoni S, Marfia GA, Masciulli C, Milano E, Moiola L, Orlandi R, Patti F, Perini P, Pesci I, Pucci E, **Puthenparampil M**, Radaelli M, Salvetti M, Sartori A, Scandellari C, Sen S, Siva A, Strumia S, Teatini F, Tedeschi G, Trojano M, Tutuncu M, Vaula G, Sormani MP, Amato MP; Musc-19 Study Group. Sars-CoV2 infection in pregnant women with multiple sclerosis. *Mult Scler*. 2023 Aug;29(9):1090-1098. doi: 10.1177/13524585231176174
50. Visentin A, **Puthenparampil M**, Briani C. Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders? *Expert Opin Investig Drugs*. 2023 Jul-Dec;32(12):1105-1111. doi: 10.1080/13543784.2023.2288076.
51. **Puthenparampil M**, Marin A, Zanotelli G, Mauceri VA, De Napoli F, Gaggiola M, Miscioscia A, Ponzano M, Bovis F, Perini P, Rinaldi F, Molon B, Gallo P. Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis. *Mult Scler Relat Disord*. 2024 Feb;82:105403. doi: 10.1016/j.msard.2023.105403.
52. **Puthenparampil M**, Stivanello C, Bano MC, Tessarin M, Martello T, Rinaldi F, Perini P, Gallo P. Telehealth Feasibility, Interest, and Satisfaction of Patients with Multiple Sclerosis Living in the Veneto Region, Italy, During the COVID-19 Pandemic. *Telemed J E Health*. 2024 Jul 25. doi: 10.1089/tmj.2024.0144
53. **Puthenparampil M**, Basili E, Ponzano M, Mauceri VA, Miscioscia A, Pilotto E, Perini P, Rinaldi F, Bovis F, Gallo P. Hyper-reflective foci changes in RRMS under natalizumab therapy. *Front Immunol*. 2024 Jul 15;15:1421755. doi: 10.3389/fimmu.2024.1421755
54. Omrani M, Chiarelli RR, Acquaviva M, Bassani C, Dalla Costa G, Montini F, Preziosa P, Pagani L, Grassivaro F, Guerrieri S, Romeo M, Sangalli F, Colombo B, Moiola L, Zaffaroni M, Pietroboni A, Protti A, **Puthenparampil M**, Bergamaschi R, Comi G, Rocca MA, Martinelli V, Filippi M, Farina C. Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomics. *Brain Behav Immun*. 2024 Oct;121:269-277. doi: 10.1016/j.bbi.2024.07.039
55. **Puthenparampil M**, Gaggiola M, Ponzano M, Zanotelli G, Miscioscia A, Nosadini M, Di Paola A, Sartori S, Perini P, Rinaldi F, Bovis F, Gallo P. High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2024 Sep;11(5):e200303. doi: 10.1212/NXI.000000000200303
56. Miscioscia A, Mainero C, Treaba CA, Silvestri E, Scialpi G, Berardi A, Causin F, Anglani MG, Rinaldi F, Perini P, **Puthenparampil M**, Bertoldo A, Gallo P. The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers. *J Neurol*. 2024 Oct;271(10):6702-6714. doi: 10.1007/s00415-024-12622-8
57. D'Ambrosio A, Zamboni S, Camerini S, Casella M, Sanchez M, Pietraforte D, Vanacore N, Diociauti M, Altieri M, Di Piero V, Francia A, Pontecorvo S, **Puthenparampil M**, Gallo P, Margutti P. Proteomic profile of extracellular vesicles from plasma and CSF of multiple sclerosis patients reveals disease activity-associated EAAT2. *J Neuroinflammation*. 2024 Sep 2;21(1):217. doi: 10.1186/s12974-024-03148-x

58. Perini P, Gaggiola M, Rinaldi F, Gallo P, **Puthenparampil M**. Relapsing tumefactive demyelination lesions: A unique, distinct inflammatory brain pathology. *Mult Scler.* 2024 Sep 8;13524585241273005. doi: 10.1177/13524585241273005
59. Kassabian B, Facco M, Miscioscia A, Carraro S, Rinaldi F, Gallo P, **Puthenparampil M**. Case report: Breaking CNS immuno-privilege: TNF α -inhibitor triggers aseptic meningitis in a patient with rheumatoid arthritis. *Front Immunol.* 2024 Sep 10; 15:1432360. doi: 10.3389/fimmu.2024.1432360
60. Musso G, Gabelli C, **Puthenparampil M**, Cosma C, Cagnin A, Gallo P, Sorarù G, Pegoraro E, Zaninotto M, Antonini A, Moz S, Zambon CF, Plebani M, Corbetta M, Basso D. Blood biomarkers for Alzheimer's disease with the Lumipulse automated platform: Age-effect and clinical value interpretation. *Clin Chim Acta.* 2024 Oct 22; 565:120014. doi: 10.1016/j.cca.2024.120014

Clinical Trials (under GCP)

I participated/participate to the following clinical trials:

1. **EFC6058 (TERACLES)**: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis Who Are Treated With Interferon-beta.
2. **101MS206 (REFINE)**: A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis (MS).
3. **AC-058B202 (ACTELION)**: Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis.
4. **WA21093A (OPERA)**: Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis.
5. **101MS328**: A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RMS).
6. **205MS302 (EXTEND)**: A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301.
7. **OCTIMS**: A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS.
8. **MA30005 (CASTING)**: an open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment.
9. **COMB157G2302 (ASCLEPIOS)**: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.
10. **CFTY720DIT15 (EVOLUTION)**: An observational, prospective, single-arm, multicenter, 24-

month study to assess MRI and clinical response on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®).

11. **GN41851 (FENhance)**: A phase iii multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide in adult patients with relapsing multiple sclerosis (Principal Investigator).
12. **EFC16035 (PERSEUS)**: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (Principal Investigator).

Research Activity

Research Group

1. Gruppo di Lavoro "Italian Alemtuzumab Study Group".
2. Progetto MUSICA: "Multiple sclerosis and the acquired demyelinating syndromes in children and adolescents: disclosing the unknown immune-pathogenetic mechanisms, identifying early signals of neurodegeneration, and translating the new acquisitions into an integrated diagnostic-therapeutic pathway.". Principal Investigator: Prof. Stefano Sartori
3. Progetto "The impact of SARS-CoV-2 epidemic on brain autoimmunity. Epidemiological and immunological study on the impact of SARS-CoV-2 on Multiple Sclerosis incidence in Padua's Province and on the intra-cerebral autoimmune response." Principal Investigator: Prof. Paolo Gallo
4. Gruppo di Lavoro "MuSC-19 Study Group" (Multiple Sclerosis and COVID-19 - MuSC-19, an international platform, linked to the Italian MS Register, to collect clinical and patient-reported data of persons with MS who have been diagnosed COVID19 or have developed symptoms (suspected COVID19).

Invited Speech

1. 05/12/19-06/12/19; Partecipazione come relatore Titolo Convegno "Alone 2019 - Alemtuzumab alla luce dell'utilizzo clinico: aggiornamento e nuove prospettive" Titolo Relazione: Immune depletion followed by reconstitution: long-term clinical impact
2. 27/05/22-27/05/22; Partecipazione a congresso come relatore. Titolo Congresso: "Condivisione di evidenze ed esperienze nella gestione della persona con SM - SyMphony" Titolo Lettura: "Profilo immunologico della persona con SM e risposta immunitaria al SARS-CoV-2"
3. 20/11/20-20/11/20; Partecipazione come relatore a convegno (Webinar), Responsabile scientifico Dr.ssa P. Perini Titolo Convegno: Primi orientamenti in era Covid Titolo Relazione: Telemedicina in era Covid: pro e contro
4. 31/03/21-31/03/21; Partecipazione come Relatore a convegno /Live webinar) Titolo Convegno: "Aubdate - è tempo di teriflunomide" Titolo Presentazione: "Il MoA di teriflunomide: immunoregolazione ed effetti immunometabolici"
5. 21/10/21-21/10/21; Partecipazione come relatore a convegno (Webinar), Responsabile scientifico Prof. Massimo Filippi Titolo Convegno: "MaveNews - una storia di innovazione" 1a edizione Titolo Presentazione Orale: "Breaking news: Last Congress highlights"

6. 10/12/21-10/12/21; Partecipazione a congresso come relatore. Titolo congresso: Sclerosi Multipla e malattie autoimmuni del SNC. Responsabile scientifico: Prof. Manganotti Lettura: Approccio diagnostico della Sclerosi Multipla: la diagnosi differenziale
7. 18/03/22-18/03/22; Responsabile scientifico e relatore al congresso: "1972-2022: 50 YEARS OF MULTIPLE SCLEROSIS IN PADUA" Titolo Lettura: "50 years of Epidemiology", nella sessione "HOW MUCH HAS MS CHANGED OVER THE LAST 50 YEARS?".
8. 25/03/22-25/03/22; Partecipazione a congresso come relatore. XXIV edizione di "Approfondimenti monotematici nella SM. Gli estremi della sclerosi multipla". Gallarate Comunicazione orale: Interruzione del trattamento - Nelle forme evolute a SP
9. 28/04/22-29/04/22; Partecipazione a congresso come relatore. Corso residenziale: "Excellence nelle manifestazioni neurologiche delle malattie reumatologiche, Padova 28-29 Aprile 2022"; Responsabile scientifico: Prof. A. Doria Lettura: "Neuriti ottiche".
10. 28/04/22-28/04/22; Partecipazione come relatore a convegno (Webinar), Responsabile scientifico Prof. Massimo Filippi Titolo Convegno: "MaveNews - una storia di innovazione" 1a edizione Titolo Presentazione Orale: "Breaking news: AAN 2022"
11. 25/05/22-25/05/22; Partecipazione come relatore Congresso ALL IN ONE – Alemtuzumab - Evidenze cliniche avanzate nel paziente ad alta attività di malattia, Roma 25 Maggio 2022 Titolo relazione: A peculiar immune ID - L'identità immunitaria del paziente ad alta attività Le
12. 09/11/22-12/11/22; Partecipazione a congresso come relatore. LXI CONGRESSO NAZIONALE SNO - Ritorno al futuro ovvero le Neuroscienze della normalità. Titolo comunicazione orale: Le terapie per la SM: visione di insieme in relazione ai meccanismi immunopatogenetici
13. 24/11/22-25/11/22; Partecipazione a congresso come relatore. Appropriatazza Terapeutica nelle Malattie Rare: Focus su Miastenia Grave e Neuromielite Ottica Lettura: Neuromielite ottica: epidemiologia, diagnosi e opzioni terapeutiche.
14. 03/12/22-06/12/22; Partecipazione a congresso come relatore. 52° CONGRESSO SOCIETÀ ITALIANA DI NEUROLOGIAMILANO 2022. Comunicazione orale (SCLEROSI MULTIPLA 1): IN PATIENTS WITH MULTIPLE SCLEROSIS RETINAL HYPER-REFLECTIVE FOCI ASSOCIATES WITH CORTICAL PATHOLOGY
15. 28/04/23-28/04/23; Partecipazione a congresso come relatore. Titolo Congresso: "SyMphony" Titolo Lettura: "Il coinvolgimento retinico nella sclerosi multipla", Padova 28.04.2023 Responsabile Scientifico: Prof. Paolo Gallo
16. 26/05/23-26/05/23; Responsabile Scientifico congresso "Pediatricando". Altri responsabili: Prof. P. Gallo, Prof. S. Sartori. Titolo comunicazione orale: "Treating pediatric-onset MS", sessione "Treating pediatric-onset demyelinating CNS disorder"
17. 17/06/23-17/06/23; Partecipazione a congresso come relatore. "Multiple Sharing". Responsabili Scientifici: Prof.ssa Maria Pia Amato, Prof.ssa Matilde Inglese, Prof. Luca Massacesi. Titolo Relazione: "I biomarkers nella SM"
18. 04/04/24-05/04/24; Partecipazione a congresso come relatore. "SPACE OF CARE As one for patients". Responsabili Scientifici: Prof. Massimo Filippi; Titolo Relazione: "Let's Talk: intervista doppia"
19. 12/04/24-12/04/24; Partecipazione a congresso come relatore. Titolo Congresso: "SyMphony" Titolo Lettura: "Ocrelizumab e la Clinica Neurologica di Padova: una lunga storia", Padova 12.04.2024 Responsabile Scientifico: Prof. Paolo Gallo.

20. 17/06/2024-17/06/2024; Partecipazione a congresso come relatore. Titolo Congresso: "Le età della Sclerosi Multipla" Titolo Lettura: "L'immunosenescenza condiziona le terapie?", Padova 17.06.2024 Responsabile Scientifico: Prof. Paolo Gallo, Dr.ssa Paola Perini.

Welfare activities

From July 2020, Dr. Puthenparampil worked at the Multiple Sclerosis Centre and at the Neurology Clinic, Azienda Ospedaliera di Padova. He is involved in the daily activity of the MS Centre at the "Day Hospital and the Center for Advanced Therapies in Neurology". Finally, he oversees the diagnostic report of the IgGOB at the Laboratory of the Neurology Clinic.

Languages

Mother tongue(s)

Italian

Other language(s)

European level ()*

English

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
C1	C1	C1	C1	B2

(*) *Common European Framework of Reference (CEF) level*

Padova, 24/10/2024

Dr. M. Puthenparampil